Biotech Series B Investors & VC Firms
900 firms in this list, with a median first check of $550K. 188 of them lead rounds. Generated from verified public data and updated continuously.
Voima Ventures
HelsinkiPre-Seed–Series B$216K – $3.2M
12 people
MassChallenge Mexico
BostonPre-Seed–Growth
29 people
TCG Crossover
Palo AltoSeed–Late Stage
25 people
ACME Capital
San FranciscoPre-Seed–Growth
12 people
European Circular Bioeconomy Fund
BonnSeries A–Late Stage$5.5M – $16.5M
24 people
BioGenerator Ventures
St. LouisPre-Seed–Series B$50K – $250K
23 people
First Analysis
ChicagoSeries A–Late Stage
23 people
BioGeneration Ventures
NaardenPre-Seed–Late Stage
27 people
Keio Innovation Initiative
TokyoSeed–Late Stage$1.5M – $64M
9 people
In-Q-Tel
TysonsSeed–Growth$100K – $2.5M
11 people
Red Tree Venture
San DiegoSeed–Series B
26 people
Argonautic Ventures
New YorkPre-Seed–Growth$5M
8 people
Booster Innovation Fund
WellingtonSeed–Growth
14 people
YuanBio Venture Capital
SuzhouSeed–Growth$3M – $73M
8 people
YFM Equity Partners
LondonSeed–Growth$3M – $15M
1 person
VenturEast
BangaloreSeed–Late Stage
12 people
Alta Partners
JacksonSeed–Growth$1M – $12M
10 people
Asabys Partners
MadridSeed–Growth
20 people
Arkin Capital
HerzliyaSeed–Late Stage
28 people
venBio Partners
San FranciscoSeed–Late Stage
9 people
Blue Horizon Corporation
ZurichPre-Seed–Late Stage
2 people
i-nest capital
TokyoPre-Seed–Growth
7 people
Kaiser Permanente Ventures
San FranciscoSeed–Growth$2M – $5M
9 people
Indaco Venture Partners
MilanSeed–Series B
17 people
Related lists
Series B Investors & VC Firms (4094)Biotech Investors & VC Firms (2107)Biotech Seed Investors & VC Firms (1754)Series B Investors & VC Firms in United States (1625)Biotech Series A Investors & VC Firms (1596)SaaS Series B Investors & VC Firms (1317)Series B Investors & VC Firms in Global (1265)Enterprise Software Series B Investors & VC Firms (1242)Healthtech Series B Investors & VC Firms (1216)Fintech Series B Investors & VC Firms (1141)
Data sourced from public filings and firms' own websites — see our methodology.












































































